Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene Editing

Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene Editing

T cells modified for expression of Chimeric Antigen Receptors (CARs) were the first gene-modified cell products approved for use in cancer immunotherapy. CAR-T cells engineered with gammaretroviral or lentiviral vectors (RVs/LVs) targeting B-cell lymphomas and leukemias have shown excellent clinical...

Full description

Bibliographic Details
Main Authors: Dimitrios L. Wagner, Ulrike Koehl, Markus Chmielewski, Christoph Scheid, Renata Stripecke
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Immunology
Subjects:
CAR-T
lentiviral
retrovirus
gene editing
GMP
CRISPR-Cas
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.865424/full

Similar Items

Similar Items